journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://www.readbyqxmd.com/read/30415298/effects-of-tiotropium-combined-with-theophylline-on-stable-copd-patients-of-group-b-d-and-its-impact-on-small-airway-function-a-randomized-controlled-trial
#1
Xiao-Feng Xiong, Li-Li Fan, Hong-Xia Wu, Min Zhu, De-Yun Cheng
INTRODUCTION: Tiotropium bromide has been widely used in clinical practice, while theophylline is another treatment option for chronic obstructive pulmonary disease (COPD). However, only a few relevant studies have investigated the long-term outcomes and efficacy of both in patients with COPD. We evaluated the effects of tiotropium and low-dose theophylline on stable COPD patients of groups B and D. METHODS: Eligible participants (n = 170) were randomized and received either tiotropium 18 µg once daily with theophylline 100 mg twice daily (Group I) or tiotropium 18 µg once daily (Group II) for 6 months...
November 10, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30415297/qualitative-and-quantitative-assessment-of-patient-and-carer-experience-of-chemotherapy-docetaxel-in-combination-with-androgen-deprivation-therapy-adt-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer-mhspc
#2
Tetsuro Ito, Laura Grant, Bryony R Duckham, Amanda J Ribbands, Adam Gater
INTRODUCTION: Recent studies suggest that docetaxel plus androgen deprivation therapy can prolong survival among men with metastatic hormone-sensitive prostate cancer (mHSPC). However, as a cytotoxic therapy, there is a need to understand the experiences of men with mHSPC receiving docetaxel and their carers in a real-world setting. METHODS: During phase 1, semi-structured qualitative interviews were conducted with men with mHSPC (n = 31) and their carers (n = 14) in Europe to elicit in-depth data concerning their experiences with docetaxel...
November 10, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30414051/cerebrolysin-for-the-treatment-of-aneurysmal-subarachnoid-hemorrhage-in-adults-a-retrospective-chart-review
#3
Yung Ki Park, Hyeong-Joong Yi, Kyu-Sun Choi, Young-Jun Lee, Dong-Won Kim, Sae Min Kwon
INTRODUCTION: Cerebrolysin is a neuroprotective drug used in the treatment of acute ischemic stroke. To our knowledge, this drug has never been evaluated in patients with aneurysmal subarachnoid hemorrhage (SAH). The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH. METHODS: Aneurysmal SAH patients who had their aneurysm obliterated at our institution from 2007 to 2016 were retrospectively studied. Patients received Cerebrolysin treatment or standard care only (control group)...
November 9, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30390239/cost-effectiveness-of-primary-prevention-with-statin-treatment-for-chinese-patients-with-type-2-diabetes
#4
Te Li, Xu Wan, Jin Ma, Bin Wu
INTRODUCTION: Statins can reduce the risk of cardiovascular events in patients with diabetes. The objective of this analysis was to evaluate whether primary prevention with statin treatment is cost-effective for newly diagnosed type 2 diabetes mellitus (T2DM) patients in the Chinese context. METHODS: An economic analysis of primary prevention with statin treatment was conducted using the Chinese Outcomes Model for T2DM with a time horizon of a lifetime, which was developed and validated based on the Chinese population...
November 2, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30387022/safety-of-excessive-visceral-fat-reduction-with-52-week-administration-of-lipase-inhibitor-orlistat-in-japanese-individuals-a-long-term-clinical-study
#5
Kohji Shirai, Michitaka Tanaka, Toru Fujita, Yuka Fujii, Masatsugu Shimomasuda, Soichi Sakai, Yoshishige Samukawa
INTRODUCTION: Orlistat is an inhibitor of pancreatic lipase and is used as an anti-obesity drug in many countries. However, there are no data available regarding the effects of orlistat on visceral fat (VF) accumulation in Japanese individuals. Therefore, this study aimed to analyze the efficacy and safety of 52 weeks of orlistat administration in Japanese individuals. METHODS: Orlistat 60 mg was administered orally three times daily for 52 weeks to Japanese participants with excessive VF accumulation and without dyslipidemia, diabetes mellitus, and hypertension (metabolic diseases)...
November 1, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30387021/correction-to-conservative-treatment-of-hemorrhoids-results-of-an-observational-multicenter-study
#6
Evgeny A Zagriadskiĭ, Alexey M Bogomazov, Evgeny B Golovko
The article "Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study", written by Evgeny A. Zagriadskiĭ, Alexey M. Bogomazov, Evgeny B. Golovko was originally published electronically on the publisher's internet portal (currently SpringerLink) on October 1, 2018 without open access.
November 1, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30374809/evaluation-of-the-responsiveness-of-the-sarqol-%C3%A2-questionnaire-a-patient-reported-outcome-measure-specific-to-sarcopenia
#7
Anton Geerinck, Olivier Bruyère, Médéa Locquet, Jean-Yves Reginster, Charlotte Beaudart
INTRODUCTION: The Sarcopenia Quality of Life (SarQoL® ) questionnaire was developed to provide a patient-reported outcome measure specific to sarcopenia. Its psychometric properties indicate that it is a valid and reliable instrument. However, until now, its ability to detect change over time has not been examined. Therefore, the objective of this study is to evaluate the responsiveness (also known as sensitivity to change) of the SarQoL® questionnaire in a prospective, longitudinal cohort of community-dwelling, older, sarcopenic subjects...
October 29, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30374808/pharmacokinetics-and-exposure-response-analyses-of-daratumumab-in-combination-therapy-regimens-for-patients-with-multiple-myeloma
#8
Xu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, P Joy Ho, Andrew Belch, Merav Leiba, Marcelo Capra, David Gomez, Eva Medvedova, Shinsuke Iida, Chang-Ki Min, Jordan Schecter, Richard Jansson, Liping Zhang, Yu-Nien Sun, Pamela L Clemens
INTRODUCTION: Daratumumab, a human IgG monoclonal antibody targeting CD38, has demonstrated activity as monotherapy and in combination with standard-of-care regimens in multiple myeloma. Population pharmacokinetic analyses were conducted to determine the pharmacokinetics of intravenous daratumumab in combination therapy versus monotherapy, evaluate the effect of patient- and disease-related covariates on drug disposition, and examine the relationships between daratumumab exposure and efficacy/safety outcomes...
October 29, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30374807/addressing-clinical-inertia-in-type-2-diabetes-mellitus-a-review
#9
REVIEW
Jennifer Okemah, John Peng, Manuel Quiñones
The current epidemic of type 2 diabetes (T2D) represents a significant global and national health concern. Globally, the prevalence of diabetes has doubled between 1980 and 2014. In 2014 the World Health Organization estimated that there were 422 million adults living with diabetes worldwide. In the USA, the number of people diagnosed with T2D is estimated to increase to over 70 million by 2050, putting an immense strain on the US healthcare system. Achieving glycemic control is widely acknowledged as the key goal of treatment in T2D and is critical for reducing the onset and progression of diabetes-related complications such as cardiovascular diseases, neuropathies, retinopathies, and nephropathies...
October 29, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30374806/emerging-therapies-for-inflammatory-bowel-disease
#10
REVIEW
Roni Weisshof, Katia El Jurdi, Nada Zmeter, David T Rubin
Inflammatory bowel disease (IBD) is a chronic heterogeneous group of diseases that has undergone major advances in the understanding of its etiology and pathogenesis in recent years. The development of biologics had resulted in better overall management of the disease, including lower rates of surgery and better long-term clinical and patient-reported outcomes. Treatment modalities have either been newly developed or extrapolated from their approved use for a different indication. Modes of action and treatment targets have varied as well...
October 29, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30374805/prospective-multicentre-trial-of-methoxyflurane-for-acute-trauma-related-pain-in-helicopter-emergency-medical-systems-and-hostile-environments-meteora-protocol
#11
Franco Marinangeli, Giorgio Reggiardo, Antonella Sblendido, Amedeo Soldi, Alberto Farina
INTRODUCTION: The inhalational analgesic low-dose methoxyflurane has been widely used by Australian ambulance services since 1975 and is now approved in Europe for emergency relief of moderate-to-severe trauma-related pain in conscious adult patients. The use of methoxyflurane in hostile environments is of special interest given its portability, ease of use and rapid onset of action. This trial will investigate the efficacy, tolerability and practicality of use of inhaled methoxyflurane in patients with moderate-to-severe trauma-related pain rescued from hostile mountainous environments by the Helicopter Emergency Medical Service (HEMS) in Italy...
October 29, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30367365/compliance-with-guidelines-on-thromboprophylaxis-for-acutely-admitted-medical-patients
#12
Nanna Freund, Jonas E Sabroe, Peter Bytzer, Søren M Madsen
INTRODUCTION: The risk of venous thromboembolism (VTE) is increased by more than 100-fold among hospitalised medical patients compared to subjects in the community. The Danish Council for the Use of Expensive Hospital Medicines has published national guidelines on thromboprophylaxis (TP) in which the risks of VTE and bleeding are balanced. We wanted to investigate the proportion of acutely admitted medical patients for whom thromboprophylaxis was indicated and to what extent the guidelines were followed...
October 26, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30357570/interpretation-and-impact-of-real-world-clinical-data-for-the-practicing-clinician
#13
REVIEW
Lawrence Blonde, Kamlesh Khunti, Stewart B Harris, Casey Meizinger, Neil S Skolnik
Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the "gold standard" for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial populations are often not representative of the patient populations encountered in clinical practice. Real-world studies may use information from electronic health and claims databases, which provide large datasets from diverse patient populations, and/or may be observational, collecting prospective or retrospective data over a long period of time...
October 24, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30350248/real-world-non-interventional-observational-study-to-evaluate-effectiveness-and-tolerability-of-acotiamide-hydrochloride-hydrate-in-treatment-of-functional-dyspepsia
#14
Shravan Kumar Porika, Krishna Chaitanya Veligandla, Shashi Kanth Muni, Shivani Acharya, Suyog C Mehta, Akhilesh D Sharma
INTRODUCTION: Functional dyspepsia (FD) is a highly prevalent condition which reduces patients' quality of life (QoL) and imparts a significant economic burden on the healthcare system. Acotiamide is a novel prokinetic agent useful in treatment of FD, and this study evaluated the effectiveness of acotiamide hydrochloride hydrate in management of FD over a 4-week period in a real-world setting. METHODS: This study was a prospective, observational, real-world data collection of 132 patients (85 male, 47 female) over 18 years of age diagnosed with FD as per Rome III criteria and treated with acotiamide for 4 weeks at a gastroenterology unit of a medical school in India...
October 22, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30341506/diurnal-and-24-h-intraocular-pressures-in-glaucoma-monitoring-strategies-and-impact-on-prognosis-and-treatment
#15
REVIEW
Anastasios G Konstas, Malik Y Kahook, Makoto Araie, Andreas Katsanos, Luciano Quaranta, Luca Rossetti, Gábor Holló, Efstathios T Detorakis, Francesco Oddone, Dimitrios G Mikropoulos, Gordon N Dutton
The present review casts a critical eye on intraocular pressure (IOP) monitoring and its value in current and future glaucoma care. Crucially, IOP is not fixed, but varies considerably during the 24-h cycle and between one visit and another. Consequently, a single IOP measurement during so-called office hours is insufficient to characterize the real IOP pathology of a patient with glaucoma. To date IOP remains the principal and only modifiable risk factor for the development and progression of glaucoma. Only by evaluating IOP characteristics (mean, peak and fluctuation of IOP) at diagnosis and after IOP-lowering interventions can we appreciate the true efficacy of therapy...
October 20, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30341505/outcomes-of-stable-multiple-sclerosis-patients-staying-on-initial-interferon-beta-therapy-versus-switching-to-another-interferon-beta-therapy-a-us-claims-database-study
#16
Stanley Cohan, Kyle Smoot, Kiren Kresa-Reahl, Robert Garland, Wei-Shi Yeh, Ning Wu, Crystal Watson
INTRODUCTION: This study was designed to assess real-world outcomes of patients with multiple sclerosis (MS) who were stable on interferon (IFN) beta therapy in the year prior to switching to another IFN beta therapy versus those who continued on the initial treatment. METHODS: This study used administrative claims from MarketScan Commercial Claims and Encounters Database, from January 1, 2010, to March 31, 2015, to identify MS patients aged 18-64 years who remained relapse free for at least 1 year while continuously treated with an IFN beta therapy...
October 20, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30341504/treatment-patterns-by-egfr-mutation-status-in-non-small-cell-lung-cancer-patients-in-the-usa-a-retrospective-database-analysis
#17
Kathleen M Aguilar, Katherine B Winfree, Catherine E Muehlenbein, Yajun Emily Zhu, Thomas Wilson, Stewart Wetmore, Eric S Nadler
INTRODUCTION: Targeted therapies, including tyrosine kinase inhibitors (TKIs) that target the sensitizing epidermal growth factor receptor (EGFR) gene are recommended for patients with non-small cell lung cancer (NSCLC). Most patients with NSCLC who test positive for the EGFR mutation and receive TKIs develop resistance to these drugs. Questions remain regarding which treatment sequence is optimal for patients with EGFR-mutant NSCLC, and few studies have evaluated patterns of TKI treatment use in NSCLC, irrespective of EGFR mutation status, in a real-world setting...
October 19, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30328062/the-safety-of-fecal-microbiota-transplantation-for-crohn-s-disease-findings-from-a-long-term-study
#18
Honggang Wang, Bota Cui, Qianqian Li, Xiao Ding, Pan Li, Ting Zhang, Xiaozhong Yang, Guozhong Ji, Faming Zhang
INTRODUCTION: Fecal microbiota transplantation (FMT) has been used as a potential treatment option for Crohn's disease (CD). However, there is still lack of safety and efficacy evidence based on large samples of CD undergoing FMT. This study aimed to evaluate the risk factors of adverse event (AE) in the long term and the efficacy of FMT in the short term for patients with CD. METHODS: FMT via mid-gut for mild to severe CD in a single center trial (NCT01793831) was performed from October 2012 to December 2016...
October 16, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30328061/cost-effectiveness-analysis-of-bezlotoxumab-added-to-standard-of-care-versus-standard-of-care-alone-for-the-prevention-of-recurrent-clostridium-difficile-infection-in-high-risk-patients-in-spain
#19
Miguel Salavert, Javier Cobo, Álvaro Pascual, Belén Aragón, Stefano Maratia, Yiling Jiang, Susana Aceituno, Santiago Grau
INTRODUCTION: Clostridium difficile infection (CDI) is the major cause of infectious nosocomial diarrhoea and is associated with considerable morbidity, mortality and economic impact. Bezlotoxumab administered in combination with standard of care (SoC) antibiotic therapy prevents recurrent CDI. This study assessed the cost-effectiveness of bezlotoxumab added to SoC, compared to SoC alone, to prevent the recurrence of CDI in high-risk patients from the Spanish National Health System perspective...
October 16, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/30328060/physical-activity-in-liver-transplantation-a-patient-s-and-physicians-experience
#20
Lara Beekman, Annalisa Berzigotti, Vanessa Banz
Liver transplantation has become a highly standardized, acceptable option for selected patients with end-stage liver disease and/or hepatocellular carcinoma in the setting of cirrhosis. Both conditions are associated with loss of skeletal muscle mass (sarcopenia) and physical deconditioning. Both conditions result in a dramatic decrease in the patients' quality of life, negatively impacting on the pre- and post-transplant prognosis. In this context, awareness of the advantages of physical activity in both the pre- and post-transplant setting is key...
October 16, 2018: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"